A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Phase 3

Terminated

• Conditions: Anemia
• Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: Epoetin alfa

• Registration Number: NCT00442416
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This 2 arm study will compare the efficacy of monthly Mircera and epoetin alfa in peritoneal dialysis patients who self-inject at home or receive in-centre injections. The safety of subcutaneous (sc) Mircera and injection site reactions and patient satisfaction will also be assessed. Eligible patients will be randomized either to receive monthly sc injections of Mircera (and will be switched from sc epoetin alfa) at a starting dose of 120-360 micrograms, or to remain on standard of care sc epoetin alfa. Dose adjustments will be permitted to reach/maintain a hemoglobin level of 10-12g/dL. The anticipated time on study treatment is 3-12 months, and the target sample size is 380 individuals.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-02
• Study First Submitted: 2007-03-01
• Study First Submitted QC: 2007-03-01
• Study First Posted: 2007-03-02
• Primary Completion: 2008-01
• Study Completion: 2008-01
• Status Verified: 2016-07
• Results First Submitted: 2016-07-05
• Results First Submitted QC: 2016-07-05
• Last Update Submitted: 2016-07-05
• Results First Posted: 2016-08-17
• Last Update Posted: 2016-08-17

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• adult patients, >=18 years of age;
• chronic kidney disease stage V;
• on peritoneal dialysis for 3 months prior to screening;
• on epoetin alfa sc >=3 months prior to screening.

Exclusion Criteria

• patients expecting to change dialysis modality over course of study;
• patients hospitalized during previous 3 months for any clinically significant condition;
• active malignancy;
• bleeding episode necessitating transfusion, or overt gastrointestinal bleeding within 3 months prior to screening;
• transfusion of red blood cells within 3 months prior to screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
RO0503821	methoxy polyethylene glycol-epoetin beta [Mircera]	Eligible participants will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta \[Mircera\]) subcutaneously (SC) every month for eight months (6 months of titration period \[TP\] and two months of evaluation period \[EP\] and 15-days following the final study visit (9 months post randomization). The first dose of Mircera (120, 200, or 360 mcg) will be based upon the dose of epoetin alfa received 1 to 2 weeks prior to administration of study drug, while subsequent doses will be adjusted to maintain haemoglobin (Hb) concentrations within target of \>=10.0 gram per decilitre (g/dL) and \<=12.0 g/dL. Participants who self-administered/visited to clinics for erythropoiesis stimulating agent (ESA) dosing prior to randomization will continue to do so.
Epoetin Alfa	Epoetin alfa	Eligible participants will be administered epoetin alfa SC as per the standard of care for eight months (TP and EP), and will be followed-up for 15 days following the final study visit. Participants who self-administered/visited to clinics for ESA dosing prior to randomization will continue to do so.

Primary Outcome Measures

Name	Time	Method
Mean Change From Baseline in Hb Concentration to Average Over the Evaluation Period	From Baseline (D 0) to 9 months	Mean change in Hb concentration from Baseline (Day \[D\] 0) to average during the evaluation period (Month 7 to 9) is reported.

Secondary Outcome Measures

Name	Time	Method
Mean Change From Baseline in Ferritin	From Baseline (D 0) to M2, M3, M4, M5, M6, M7, M8	Adequate iron status is prerequisite to achieve and maintain target Hb levels. Mean change from Baseline (D 0) in ferritin to D1 of M2, 3, 4, 5, 6, 7, and 8 is reported.
Mean Change From Baseline in Transferrin Saturation	From Baseline (D 0) to M2, M3, M4, M5, M6, M7, M8	Adequate iron status is prerequisite to achieve and maintain target Hb levels. Mean change from Baseline (D 0) in transferrin to D1 of M2, 3, 4, 5, 6, 7, and 8 is reported.
Mean Change From Baseline in Serum Transferrin	From Baseline (D 0) to M2, M3, M4, M5, M6, M7, M8	Adequate iron status is prerequisite to achieve and maintain target Hb levels. Mean change from Baseline (D 0) in serum transferrin to D1 of M2, 3, 4, 5, 6, 7, and 8 is reported.
Mean Change From Baseline in Pulse Rate	From Baseline (D 0) to D1 and D15 of M7, M8
Mean Change From Baseline in Weight	From Baseline (D 0) to D1 and D15 of M7, M8
Number of Participants With Anti-RO0503821 Antibody in Human Serum	Up to Month 9	RO0503821 is a chemically modified erythropoietin which helps to make more RBCs and is used for the treatment of anemia of chronic kidney disease. However, during treatment with RO0503821, anti-RO0503821 antibody may develop in human serum. These antibodies have been shown to cross-react with all ESAs and leads to failure to respond. Number of participants with anti- RO0503821 antibody that are quantifiable and those that were "BLQ" at Baseline (Day 0) and Visit 17 (M 9) or final visit/early termination in human serum samples are reported.
Percentage of Participants With Safety-Related Hb Measures	Up to Month 9	Safety-related Hb measures included percentage of participants with Hb value \> 13 g/dL, 13.5 g/dL, increase in Hb value from baseline by \> 2 g/dL or decrease in Hb value from baseline by \> 2 g/dL at any time during the study.
Number of Participants With Marked Laboratory Abnormalities	Up to Month 9	Participants with marked laboratory abnormalities in hematology and clinical chemistry parameters are reported. Hematology laboratory parameters included hematocrit fraction, hemoglobin, platelets, white blood cells (WBCs) and clinical chemistry parameters included aspartate aminotransferase (\[AST\], alanine aminotransferase (\[ALT\], creatine phosphokinase (CPK), alkaline phosphatase, albumin, potassium, fasting glucose and phosphate.
Mean Change From Baseline in Total Iron-binding Capacity	From Baseline (D 0) to M2, M3, M4, M5, M6, M7, M8	Adequate iron status is prerequisite to achieve and maintain target Hb levels. Mean change from Baseline (D 0) in total Iron-binding Capacity to D1 of M2, 3, 4, 5, 6, 7, and 8 is reported.
Mean Change From Baseline in Iron	From Baseline (D 0) to Month (M) 2, M3, M4, M5, M6, M7, M8	Adequate iron status is prerequisite to achieve and maintain target Hb levels. Mean change from Baseline (D 0) in iron to D1 of Months 2, 3, 4, 5, 6, 7, 8 is reported.
Mean Change From Baseline in Temperature	From Baseline (D 0) to D1 and D15 of M7, M8
Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure	From Baseline (D 0) to D1 and D15 of M7, M8
Number of Participants With Anti-erythropoietin Antibody in Human Serum	Up to Month 9	Erythropoietin is human protein which helps to make more RBCs and is used for the treatment of anemia of chronic kidney disease. However, during treatment with erythropoietin, anti-erythropoietin antibody (Anti-EPO) may develop in human serum. These antibodies have been shown to cross-react with all ESAs and leads to failure to respond to treatment. Number of participants with anti-EPO antibody that are quantifiable and those that were "below the limit of quantification (BLQ)" at Baseline (Day 0) and Visit 17 (Month 9 \[M 9\]) or final visit/early termination in human serum samples are reported.
Number of Participants With Any AEs, Any Serious Adverse Events and Death	Up to 9 months	An AE is untoward medical occurrence in a participant who received the study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is with any of the following outcomes: Death, initial or prolonged inpatient hospitalisation, life-threatening experience, persistent or significant disability/incapacity; congenital anomaly.